Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention
- 8 August 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 46 (5) , 761-769
- https://doi.org/10.1016/j.jacc.2005.03.073
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevationJournal of the American College of Cardiology, 2005
- Economic effects of prolonged clopidogrel therapy after percutaneous coronary interventionJournal of the American College of Cardiology, 2005
- Estimating Survival for Cost-Effectiveness Analyses: A Case Study in AtherothrombosisValue in Health, 2004
- 889-3 Estimating life-years lost due to atherothrombotic events: Flexible survival functions for use in disease modelingJournal of the American College of Cardiology, 2004
- Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist eraAmerican Heart Journal, 2003
- Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart DiseaseNew England Journal of Medicine, 2002
- A cardiovascular life historyPublished by Oxford University Press (OUP) ,2002
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996
- Covariance adjustment of survival curves based on Cox′s proportional hazards regression modelBioinformatics, 1992
- Adjusted survival curve estimation using covariatesJournal of Chronic Diseases, 1982